35 results
8-K
EX-99.1
PCSA
Processa Pharmaceuticals Inc
3 Oct 18
Processa Pharmaceuticals Receives Fda Clearance
12:00am
presents more commonly in women than in men and ulceration can occur in approximately 30% of NL patients. More severe complications can occur
8-K
EX-99.1
PCSA
Processa Pharmaceuticals Inc
4 Aug 22
Regulation FD Disclosure
9:30am
in individuals with diabetes and women, with an average age of onset between 20 and 60 years. People with NL experience a persistent skin condition
8-K
EX-99.1
PCSA
Processa Pharmaceuticals Inc
30 Mar 18
License for the Clinical Stage Compound CTP-499 and Plans to Develop
12:00am
), a chronic, disfiguring condition for which most patients do not have any treatment options. NL develops more commonly in women than in men on the pretibial
8-K
EX-99.1
PCSA
Processa Pharmaceuticals Inc
19 Jan 24
Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer
8:00am
last year. Over 150,000 women are currently living with advanced or metastatic breast cancer. The NGC-Cap potential market for breast, colorectal
424B4
8bld5nsp1 b2yhoqyd15
5 Oct 20
Prospectus supplement with pricing info
4:16pm